Respiri (ASX:RSH) has become the first Australian medical device manufacturer to have its patented device, used for Remote Patient Monitoring (RPM) programs prescribed by physicians, to be successfully processed and be receiving reimbursement from Centers of Medicare and Medicaid Services (CMS) in the USA.
The eHealth SaaS Company supporting respiratory health management says wheezo® is currently being used by 20 patients and 500 more are expected to be onboarded soon.
Respiri says it earns US$50-60 for each device sale and US$10-20 per month from the ongoing RPM use of the device.
It says CMS provides universal reimbursement coverage for eligible patients across all 50 US states and 28 states mandate RPM reimbursement.